ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

クロナゼパム

Clonazepam

HCID 2802
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
106955-87-7
標準SMILES
O=C1CN=C(c2ccccc2Cl)c2cc([N+](=O)[O-])ccc2N1
InChIKey
DGBIGWXXNGSACT-UHFFFAOYSA-N
分子式
C15H10ClN3O3
平均分子量
315.71 g/mol
単同位体質量
315.0410689

概要

Clonazepam is 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation. It has a role as an anxiolytic drug, an anticonvulsant and a GABA modulator. It is a 1,4-benzodiazepinone and a member of monochlorobenzenes.

名称と識別子

優先名称
Clonazepam
IUPAC
5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one
現地名
クロナゼパム
英語名
Clonazepam
分子式
C15H10ClN3O3
分子量
315.71

名称と別名

clonazepamKlonopinRivotril1622-61-3ChlonazepamIktorivilCloazepamClonazepamumRavotrilRivatril5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-oneRo 4-8180
名称をさらに表示
クロノピン5-[2-クロロフェニル]-7-ニトロ-1H-1,4-ベンゾジアゼピン-2(3H)-オン5-(o-クロロフェニル)-7-ニトロ-2,3-ジヒドロ-1H-1,4-ベンゾジアゼピン-2-オン5-(2-クロロフェニル)-7-ニトロ-1H-1,4-ベンゾジアゼピン-2(3H)-オン1,3-ジヒドロ-7-ニトロ-5-(2-クロロフェニル)-2H-1,4-ベンゾジアゼピン-2-オンリボトリルクロナゼパムイクトリビル7-ニトロ-5-(2-クロロフェニル)-1H-1,4-ベンゾジアゼピン-2(3H)-オンリボトリールランドセン5-(2-クロロフェニル)-1,3-ジヒドロ-7-ニトロ-2H-1,4-ベンゾジアゼピン-2-オンクロナゼパム 溶液クロナゼパム錠クロナゼパム細粒クロナゼパム (JP17)クロナゼパム錠 (JP17)クロナゼパム細粒 (JP17)5-(2-クロロフェニル)-7-ニトロ-2,3-ジヒドロ-1H-1,4-ベンゾジアゼピン-2-オン5-(2-chlorophenyl)-1,3-dihydro-7-nitro-2h-4-benzodiazepin-2-oneRO4023SentilLandsenRivotriClonopinro4-8180
Klonopin Rapidly DisintegratingClonazepam civ5-(2-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one2H-1,4-Benzodiazepin-2-one, 5-(2-chlorophenyl)-1,3-dihydro-7-nitro-Ro-5-40231,3-Dihydro-7-nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-oneRo 540235-(o-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one

物性

構造計算による物性

XLogP
2.4
極性表面積
87.3 Ų
水素結合供与体数
1
水素結合受容体数
4
回転可能結合数
1
重原子数
22
形式電荷
0
複雑度
491

実験および物理化学的性質

Drugs · 6 件

DEA NFLIS-Drug Category -> Benzodiazepines

DEA Schedule IV Controlled Substance -> Depressants

Pharmaceuticals

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Benzodiazepines

Pharmaceuticals -> Synthetic Cannabinoids or Psychoactive Compounds

LogP · 3 件

log Kow = 2.41

2.7

2.5

OdorFaint odor
Color/Form · 2 件

White crystals from ethanol-methylene chloride

Off-white to light yellow crystalline powder

Solubility · 4 件

In water, <100 mg/L at 25 °C

Insoluble in benzene; slightly soluble in acetone, methanol, chloroform

Solubility in mg/mL at 25 °C: acetone 31; chloroform 15; methanol 8.6; ether 0.7; benzene 0.5

1.06e-02 g/L

Human Drugs · 4 件

Breast Feeding; Lactation; Milk, Human; Anticonvulsants; Benzodiazepines

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

DecompositionWhen heated to decomposition it emits very toxic fumes of /hydrogen chloride and nitrogen oxides/.

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 5 件

This chemical does not meet GHS hazard criteria for 12.5% (1 of 8) of reports.

Danger

H336 (50%): May cause drowsiness or dizziness [Warning Specific target organ toxicity, single exposure; Narcotic effects]

P203, P260, P261, P263, P264, P270, P271, P273, P280, P304+P340, P318, P319, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 8 reports by companies from 8 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory Information · 2 件

DEA schedule IV controlled substance

Clonazepam: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Other Safety InformationIMAP assessments - 2H-1,4-Benzodiazepin-2-one, 5-(2-chlorophenyl)-1,3-dihydro-7-nitro-: Environment tier I assessment
FDA Requirements · 2 件

Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it. ... Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: Clonazepam (DEA Code Number: 2737) is included on this list.

The Approved Drug Products with Therapeutic Equivalence Evaluations identifies currently marketed prescription drug products, including clonazepam, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

化学と産業

薬理情報

ATC Code · 3 件

N03AE01

N - Nervous system

QN - Nervous system

Protein BindingThe recorded plasma protein binding of clonazepam ranges between 82–86%.
Pharmacodynamics · 1 件

The pharmacodynamic properties of clonazepam are common among benzodiazepines and include anticonvulsive, sedative, muscle relaxing and anxiolytic effects. Animal data and electroencephalographic investigations in man have shown that clonazepam rapidly suppresses many types of paroxysmal activity including the spike and wave discharge in absence seizures (petit mal), slow spike wave, generalized spike wave, spikes with temporal or other locations, as well as irregular spikes and waves. Moreover, the agent can also decrease the frequency, amplitude, duration, and spread of discharge in minor motor seizures. Generalized EEG abnormalities are more readily suppressed by clonazepam than are focal EEG abnormalities such as focal spikes. Clonazepam has beneficial effects in generalized and focal epilepsies.

Mechanism of Action · 1 件

Gamma-Aminobutyric acid (GABA) is considered the principal inhibitory neurotransmitter in the human body. When GABA binds to GABA(a) receptors found in neuron synapses, chloride ions are conducted across neuron cell membranes via an ion channel in the receptors. With enough chloride ions conducted, the local, associated neuron membrane potentials are hyperpolarized - making it more difficult or less likely for action potentials to fire, ultimately resulting in less excitation of the neurons. Subsequently, benzodiazepines like clonazepam can bind to benzodiazepine receptors that are components of various varieties of GABA(a) receptors. This binding acts to enhance the effects of GABA by increasing GABA affinity for the GABA(a) receptor, which ultimately enhances GABA ligand binding at the receptors. This enhanced ligand binding of the inhibitory neurotransmitter GABA to the receptors increases the aforementioned chloride ion conduction (perhaps reportedly via an increase in the frequency of the chloride channel opening), resulting in a hyperpolarized cell membrane that prevents further excitation of the associated neuron cells. Combined with the notion that such benzodiazepine receptor associated GABA(a) receptors exist both peripherally and in the CNS, this activity consequently facilitates various effects like sedation, hypnosis, skeletal muscle relaxation, anticonvulsant activity, and anxiolytic action. In particular, when out of the ordinary rapid and repetitive electrical signals are released in the CNS, it is proposed that the brain can become over-stimulated and ordinary functions are disrupted - resulting in seizure activity. By enhancing the neuro-inhibitory activity of GABA, it is believed that clonazepam can facilitate in decreasing any excessive electrical nerve activity in the CNS that might be contributing to seizures. Concurrently, it is also believed that clonazepam's actions in enhancing GABA effects may inhibit neuronal activity proposed to occur in amygdala-centered fear circuits - therefore assisting in the management of anxiety or panic.

関連反応

14 件
反応記録を作成
HRID 328498 の反応式
HRID 328498反応物として
HRID 597631 の反応式
HRID 597631反応物として
HRID 649265 の反応式
HRID 649265反応物として
HRID 663423 の反応式
HRID 663423反応物として
HRID 725666 の反応式
HRID 725666生成物として
HRID 1208780 の反応式
HRID 1208780反応物として
HRID 1557187 の反応式
HRID 1557187反応物として
HRID 1557848 の反応式
HRID 1557848反応物として
前へ1 / 2 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
106955-87-7、1622-61-3
PubChem CID
2802
DTXSID
DTXSID1022845
ChEMBL
CHEMBL452
ChEBI
CHEBI:3756
UNII
5PE9FDE8GB
EC Number
216-596-2
Nikkaji
J5.233G
Melting Point · 3 件

238-240

237.5 °C

236.5 - 238.5 °C

Physical DescriptionSolid
Stability/Shelf Life · 2 件

The commercially available conventional tablets have an expiration date of 5 years following the date of manufacture.

Stable under recommended storage conditions.

Dissociation ConstantspK1 = 1.5; pK2 = 10.5
Collision Cross Section · 2 件

168.2 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

171 Ų [M+H]+ [CCS Type: DT; Method: single field calibrated]

物理化学的性質

融点
236.5 · 236.5-238.50C
沸点
524.5 · 524.5±50.0 °C(Predicted)
比重(密度)
1.4592 · 1.4592 (rough estimate)
屈折率
1.647 · 1.6470 (estimate)
闪点
11 °C · 11 °C
貯蔵温度
2 · 2-8°C
溶解性
水にほとんど溶けず、アルコールとメタノールに溶けにくい。
外見
粉
酸解離定数(Pka)
1.5 · 1.5, 10.5(at 25℃)
色
ライトイエロー
Henry's Law Constant
1.4 · 1.4×107 mol/(m3Pa) at 25℃, HSDB (2015)
主な用途
医薬品(低分子化合物)
InChI
1S/C15H10ClN3O3/c16-12-4-2-1-3-10(12)15-11-7-9(19(21)22)5-6-13(11)18-14(20)8-17-15/h1-7H,8H2,(H,18,20)
InChIKey
DGBIGWXXNGSACT-UHFFFAOYSA-N
SMILES
Clc1ccccc1C2=NCC(=O)Nc3ccc(cc23)N(=O)=O
CAS データベース
1622 · 1622-61-3(CAS DataBase Reference)
NISTの化学物質情報
Clonazepam(1622-61-3)
EPAの化学物質情報
2 H-1,4-Benzodiazepin-2-one, · 2H-1,4-Benzodiazepin-2-one, 5-(2-chlorophenyl)-1,3-dihydro-7-nitro- (1622-61-3)

化学的性質

化学的特性Tan Solid

Special Reports · 2 件

Teboul E, Chouinard G; A Guide to Benzodiazepine Selection. Part II: Clinical Aspects. Can J Psychiatry 36 (1): 62-73 (1991). To suit the specific needs of various clinical situations, selection of an appropriate benzodiazepine derivative should be based on consideration of their different pharmacokinetic and pharmacodynamic properties. Benzodiazepine derivatives that are rapidly eliminated produce the most pronounced rebound and withdrawal syndromes. Benzodiazepines that are slowly absorbed and slowly eliminated are most appropriate for the anxious patient, since these derivatives produce a gradual and sustained anxiolytic effect. Rapidly absorbed and slowly eliminated benzodiazepines are usually more appropriate for patients with sleep disturbances, since the rapid absorption induces sleep and the slower elimination rate may induce less tolerance to the sedative effect. Rational selection of a benzodiazepine for the elderly and for the suspected drug abuser is more problematic. The relevant pharmacokinetic and clinical considerations for these users are discussed. Certain derivatives may possess pharmacodynamic properties not shared by the entire benzodiazepine class; empirical studies have suggested the existence of anti-panic properties for alprazolam and clonazepam, antidepressant properties for alprazolam, and anti-manic properties for clonazepam and possibly lorazepam.

Trimble MR, Cull C; Children of School age: The Influence of Antiepileptic Drugs on Behavior and Intellect. Epilepsia 29 (Suppl 3): S15-9 (1988). The role of antiepileptic drugs in behavior and cognitive function in children is well documented the literature. In general, behavioral problems occur most frequently with phenobarbital and clonazepam, and appear least often with valproate and carbamazepine. Cognitive impairments occur with phenytoin, are less evident with valproate, and minimal with carbamazepine. Monotherapy, as with adults, leads to improvements in both cognitive abilities and behavior.

Toxic Combustion ProductsSpecial hazards arising from the substance or mixture: Carbon oxides, nitrogen oxides (NOx), hydrogen chloride gas.
Hazard Classes and CategoriesSTOT SE 3 (50%)

安全と保護具

Fire Fighting Procedures · 2 件

Suitable extinguishing media: Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

Advice for firefighters: Wear self contained breathing apparatus for fire fighting if necessary.

Storage Conditions · 2 件

Keep container tightly closed in a dry and well-ventilated place.

Clonazepam tablets and orally disintegrating tablets should be stored in air-tight, light-resistant containers at 25 °C, but may be exposed to temperatures ranging from 15-30 °C. The commercially available conventional tablets have an expiration date of 5 years following the date of manufacture.

Cleanup Methods · 1 件

ACCIDENTAL RELEASE MEASURES: Personal precautions, protective equipment and emergency procedures: Avoid dust formation. Avoid breathing vapors, mist or gas. Environmental precautions: Do not let product enter drains. Methods and materials for containment and cleaning up: Sweep up and shovel. Keep in suitable, closed containers for disposal.

Disposal Methods · 2 件

SRP: Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.

Product: Offer surplus and non-recyclable solutions to a licensed disposal company. Contaminated packaging: Dispose of as unused product.

Preventive Measures · 5 件

ACCIDENTAL RELEASE MEASURES: Personal precautions, protective equipment and emergency procedures: Avoid dust formation. Avoid breathing vapors, mist or gas. Environmental precautions: Do not let product enter drains.

Precautions for safe handling: Provide appropriate exhaust ventilation at places where dust is formed. Normal measures for preventive fire protection.

Appropriate engineering controls: General industrial hygiene practice.

Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands.

SRP: Local exhaust ventilation should be applied wherever there is an incidence of point source emissions or dispersion of regulated contaminants in the work area. Ventilation control of the contaminant as close to its point of generation is both the most economical and safest method to minimize personnel exposure to airborne contaminants. Ensure that the local ventilation moves the contaminant away from the worker.

Personal Protective Equipment (PPE) · 4 件

Eye/face protection: Safety glasses with side-shields conforming to EN166. Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).

Skin protection: Handle with gloves.

Body Protection: Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and to the specific work-place.

Respiratory protection: Respiratory protection is not required. Where protection from nuisance levels of dusts are desired, use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).

毒性情報

Body BurdenCord and maternal serum levels of clonazepam at delivery were 32 and 19 ng/mL in a woman that had been treated with clonazepam throughout her pregnancy (36 weeks)(1). Clonazepam was detected at 11-13 ng/mL in breast milk from this woman(1).
Treatment · 1 件

Treatment includes monitoring of respiration, pulse and blood pressure, general supportive measures and immediate gastric lavage. Intravenous fluids should be administered and an adequate airway maintained. Hypotension may be combated by the use of levarterenol or metaraminol. Flumazenil, a specific benzodiazepine-receptor antagonist, is indicated for the complete or partial reversal of the sedative effects of benzodiazepines and may be used in situations when an overdose with a benzodiazepine is known or suspected. (L1712)

Interactions · 5 件

Increased salivation, hypersecretion in upper respiratory passages, chest congestion, rhinorrhea, and shortness of breath may occur in patients receiving clonazepam. In one study, increased salivation, mucous obstruction of the nasopharynx and bronchi, and difficulty in swallowing occurred in infants receiving the drug. The investigator reported that these effects occurred most frequently when clonazepam was used in conjunction with phenobarbital.

The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites, and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and follow patients closely for respiratory depression and sedation.

Additive CNS depression may occur when clonazepam is administered concomitantly with other CNS depressants, including alcohol, opiate agonists, barbiturates, anxiolytics, sedatives and hypnotics, some antipsychotic agents, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants, and other anticonvulsants. If clonazepam is used concomitantly with other CNS depressants, caution should be used to avoid excessive CNS depression. Patients also should be advised to avoid alcohol while receiving clonazepam therapy.

In one study, increased serum phenytoin concentrations were reported to occur when clonazepam and phenytoin were administered concomitantly. In another study, plasma clonazepam concentrations decreased when the two drugs were administered. Although the clinical importance of these reports has not been established, it may be desirable to monitor serum concentrations of both drugs during initial concomitant therapy, making dosage adjustments as necessary.

For more Interactions (Complete) data for Clonazepam (8 total), please visit the HSDB record page.

Health EffectsMay cause a potentially dangerous rash that may develop into Stevens Johnson syndrome, an extremely rare but potentially fatal skin disease.
Hepatotoxicity · 1 件

Clonazepam, as with other benzodiazepines, is rarely associated with serum ALT elevations, and clinically apparent liver injury from clonazepam is extremely rare. However, at least one convincing case report of acute liver injury from clonazepam with recurrence on reexposure has been reported. Rare instances of drug induced liver injury has been reported with other benzodiazepines, such as chlordiazepoxide, diazepam, flurazepam, triazolam, clorazepate and alprazolam. In benzodiazepine related cases of acute liver injury, the latency has ranged from a few weeks to 6 months; the typical pattern of liver enzyme elevations has been cholestatic or mixed, but hepatocellular patterns have also been reported. The injury is usually mild to moderate in severity and self-limited. Fever and rash have not been described nor has autoantibody formation.

Environmental Fate · 3 件

TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 12,000(SRC), determined from a structure estimation method(2), indicates that clonazepam is expected to be immobile in soil(SRC). Volatilization of clonazepam from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of 7.0X10-13 atm-cu m/mole(SRC), using a fragment constant estimation method(2). Clonazepam is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 7.3X10-11 mm Hg at 25 °C(SRC), determined from a fragment constant method(2). Biodegradation data in soil were not available(SRC, 2017).

AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 12,000(SRC), determined from a structure estimation method(2), indicates that clonazepam is expected to adsorb to suspended solids and sediment(SRC). Volatilization from water surfaces is not expected(3) based upon an estimated Henry's Law constant of 7.0X10-13 atm-cu m/mole(SRC), developed using a fragment constant estimation method(2). Clonazepam is not expected to undergo hydrolysis in the environment due to the lack of functional groups that hydrolyze under environmental conditions(3). According to a classification scheme(4), an estimated BCF of 18(SRC), from its log Kow of 2.41(5) and a regression-derived equation(2), suggests the potential for bioconcentration in aquatic organisms is low. Biodegradation data in water were not available(SRC, 2017).

ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), clonazepam, which has an estimated vapor pressure of 7.3X10-11 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase clonazepam may be removed from the air by wet or dry deposition(SRC). Clonazepam contains chromophores that absorb at wavelengths >290 nm(3) and, therefore, may be susceptible to direct photolysis by sunlight(SRC).

Adverse EffectsThe adverse effects of clonazepam derive from its property to act as a central nervous system depressant like all the other BZD drugs.
Exposure RoutesClonazepam is rapidly and completely absorbed after oral administration. The absolute bioavailability of clonazepam is about 90%. Cmax, oral administration = 1 -4 hours.
Milk ConcentrationsClonazepam was detected at 11-13 ng/mL in breast milk from a woman that had been treated with clonazepam throughout her pregnancy (36 weeks)(1).
Toxicity Summary · 3 件

IDENTIFICATION AND USE: Clonazepam is off-white to light yellow crystalline powder with a faint odor. It is a Schedule IV Controlled Substance. It is anticonvulsant and gamma-aminobutyric acid (GABA) modulator. A significant increase in the illegal use of clonazepam has been seen. HUMAN STUDIES: Overdosage of clonazepam may produce somnolence, confusion, ataxia, diminished reflexes, or coma. The shortcomings of clonazepam therapy include tolerance, withdrawal symptoms, and adverse effects such as drowsiness, dizziness, and confusion leading to increased risk of falls. Inter-individual variability in the incidence of adverse events in patients partly originates from the differences in clonazepam metabolism due to genetic and nongenetic factors. Because of experience with other members of the benzodiazepine class, clonazepam is assumed to be capable of causing an increased risk of congenital abnormalities when administered to a pregnant woman during the first trimester. In a study of 118 liveborn infants, there were 6 (5.1%) with major malformations, 4 of whom were prenatally exposed to clonazepam monotherapy and all of whom were full term infants. These included two with bilateral inguinal hernias requiring surgery, one with bilateral communicating hydroceles requiring surgery, one with midline pit over the nasal bridge, one with a uretero-pelvic junction obstruction requiring surgery and one with a PDA and ASD diagnosed at one day of age for which no follow-up is available. Sixty five (55.1%) of liveborn infants received a dysmorphological exam performed by an examiner who was blinded to the prenatal exposure. Although 16 (13.6%) children had 3 or more minor malformations, only one of the 16 was exposed to monotherapy. It is notable that 3 fullterm infants, all of whom were prenatally exposed to clonazepam monotherapy, had either inguinal hernias or communicating hydroceles requiring surgery. ANIMAL STUDIES: No adverse maternal or embryo-fetal effects were observed in mice and rats following oral administration during organogenesis of doses up to 15 mg/kg/day or 40 mg/kg/day, respectively. In a two-generation fertility study in which clonazepam was given orally to rats at 10 and 100 mg/kg/day, there was a decrease in the number of pregnancies and in the number of offspring surviving until weaning. In three studies in which clonazepam was administered orally to pregnant rabbits at doses of 0.2, 1, 5 or 10 mg/kg/day during the period of organogenesis, a similar pattern of malformations (cleft palate, open eyelid, fused sternebrae and limb defects) was observed in a low, non-dose-related incidence in exposed litters from all dosage groups. Reductions in maternal weight gain occurred at dosages of 5 mg/kg/day or greater and reduction in embryo-fetal growth occurred in one study at a dosage of 10 mg/kg/day. Of 1214 dogs exposed to clonazepam, 725 were symptomatic with 74% being ataxic, 33% sedated 21% agitated and 11% vomiting. Of 119 cats exposed to clonazepam, 85 were symptomatic with 85% being ataxic, 27% agitated and 27% sedated.

Signs and SymptomsSomnolence, confusion, coma, and diminished reflexes. The most commonly reported adverse event when clonazepam is used for seizure disorders is CNS depression.
Effluent ConcentrationsClonazepam was detected in 9% of effluent samples collected in 2010 from 90 European wastewater treatment plants at <5-43.7 ng/L (average 1.6 ng/L)(1). Based on studies, clonazepam removal is about 10.3% in wastewater treatment plants(2).

法規制情報

FDA Requirements · 2 件

Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it. ... Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: Clonazepam (DEA Code Number: 2737) is included on this list.

The Approved Drug Products with Therapeutic Equivalence Evaluations identifies currently marketed prescription drug products, including clonazepam, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

安全データ

wgk
2
rtecs
DF2100000
ridadr
UN 1230 3/PG 2
毒性
LD50 orally in mice: >4000 mg/kg (Blum)
hs_code
2933990099
risk_code
11-23/24/25-39/23/24/25
hazard_code
F,T
safety_code
7-16-36/37-45-24/25-22
hazard_class
6.1(b)
packing_group
III
Hazard Classifications
Aquatic Chronic 3STOT SE 3
ストレージクラス
11 - Combustible Solids
有毒物質データの
1622-61-3(Hazardous Substances Data)
Biological Half-Life · 2 件

The mean elimination half-life determined for clonazepam is independent of the dose given and has been documented as being about 30-40 hours.

Elimination half-life ... 18.7 to 39 hr.

Metabolism/Metabolites · 4 件

Clonazepam is metabolized principally in the liver. The metabolic pathways include hydroxylation, reduction of the nitro groups to amine groups, and the addition of acetate to the amino grouping. In particular, clonazepam is extensively metabolized by reduction to 7-amino-clonazepam and by N-acetylation to 7-acetamido-clonazepam. Hydroxylation at the C-3 position also occurs. Hepatic cytochrome P450 3A4 is implicated in the nitroreduction of clonazepam to pharmacologically inactive metabolites.

The shortcomings of clonazepam therapy include tolerance, withdrawal symptoms, and adverse effects such as drowsiness, dizziness, and confusion leading to increased risk of falls. Inter-individual variability in the incidence of adverse events in patients partly originates from the differences in clonazepam metabolism due to genetic and nongenetic factors. Since the prominent role in clonazepam nitro-reduction and acetylation of 7-amino-clonazepam is assigned to CYP3A and N-acetyl transferase 2 enzymes, respectively, the association between the patients' CYP3A status (CYP3A5 genotype, CYP3A4 expression) or N-acetyl transferase 2 acetylator phenotype and clonazepam metabolism (plasma concentrations of clonazepam and 7-amino-clonazepam) was evaluated in 98 psychiatric patients suffering from schizophrenia or bipolar disorders. The patients' CYP3A4 expression was found to be the major determinant of clonazepam plasma concentrations normalized by the dose and bodyweight (1263.5 +/- 482.9 and 558.5 +/- 202.4 ng/mL per mg/kg bodyweight in low and normal expressers, respectively, P<0.0001). Consequently, the dose requirement for the therapeutic concentration of clonazepam was substantially lower in low-CYP3A4 expresser patients than in normal expressers (0.029 +/- 0.011 vs 0.058 +/- 0.024 mg/kg bodyweight, P<0.0001). Furthermore, significantly higher (about 2-fold) plasma concentration ratio of 7-amino-clonazepam and clonazepam was observed in the patients displaying normal CYP3A4 expression and slower N-acetylation than all the others. Prospective assaying of CYP3A4 expression and N-acetyl transferase 2 acetylator phenotype can better identify the patients with higher risk of adverse reactions and can facilitate the improvement of personalized clonazepam therapy and withdrawal regimen.

Clonazepam is extensively metabolized in the liver to several metabolites including 7-aminoclonazepam, 7-acetaminoclonazepam, and 3-hydroxy derivatives of these metabolites and clonazepam. Clonazepam metabolites are excreted in urine by first-order kinetics, principally as their glucuronide and/or sulfate conjugates.

Hepatic (cytochrome P450, including CYP3A). Biotransformation occurs mainly by reduction of the 7-nitro group to the 4-amino derivative. This derivative can be acetylated, hydroxylated, and glucuronidated. Route of Elimination: Clonazepam is highly metabolized, with less than 2% unchanged clonazepam being excreted in the urine. Metabolites of Klonopin are excreted by the kidneys. Clonazepam also undergoes acetylation via NAT2. Half Life: 30-40 hours

FDA Pharmacological Classification · 6 件

5PE9FDE8GB

CLONAZEPAM

Established Pharmacologic Class [EPC] - Benzodiazepine

Chemical Structure [CS] - Benzodiazepines

Clonazepam is a Benzodiazepine.

CLONAZEPAM

MeSH Pharmacological Classification · 2 件

Drugs used to prevent SEIZURES or reduce their severity.

Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here.

Absorption, Distribution and Excretion · 6 件

Clonazepam is rapidly and almost entirely absorbed after oral administration as tablets. Peak plasma concentrations of clonazepam administered by the oral route are reached within 1-4 hours and the associated absorption half-life is about 25 minutes. The absolute bioavailability is approximately 90% - but with substantially large differences between individuals.

Approximately 50-70% of a clonazepam dose is excreted in the urine and 10-30% is excreted in the feces as metabolites. The excretion of unchanged clonazepam in the urine is typically less than 2% of the administered dose. Metabolites of clonazepam are present in urine as both free and conjugated (glucuronide and sulfate) compounds.

Clonazepam distributes very rapidly to various organs and body tissues with preferential uptake by brain structures. The apparent volume of distribution has been documented as approximately 3 L/kg.

The documented clearance for clonazepam is approximately 55 ml/min regardless of gender. Nevertheless, clearance values normalized by weight decline with increasing body weight.

/MILK/ A 2750-g female infant was born at 36 weeks' gestation to a 40-year-old woman treated with clonazepam throughout her pregnancy. The infant developed apnea, cyanosis, and hypotonia within a few hours of birth. The mother's serum clonazepam level at delivery was 32 ng/mL; the cord blood level was 19 ng/mL. The infant had no congenital malformations, evidence of infection, or seizures. Clinical episodes ceased by ten days of age. The woman elected to breastfeed; breast milk clonazepam levels were between 11 and 13 ng/mL. She was discharged with a cardiorespiratory monitor. The authors suggest that infants of mothers receiving this agent during pregnancy or while nursing have serum levels measured. Additionally, these infants should be monitored for central nervous system depression or apnea.

Clonazepam is rapidly and well absorbed from the GI tract. The absolute bioavailability is approximately 90%. In one study, peak blood concentrations of 6.5-13.5 ng/mL were usually reached within 1-2 hours following a single 2 mg oral dose of micronized clonazepam in healthy adults. In some individuals, however, peak blood concentrations were reached at 4-8 hours. Although the plasma concentration of clonazepam required for anticonvulsant effects has not been definitely established, some studies indicate it may be 20-80 ng/mL. Plasma concentrations in this range have been reported to be maintained in adults receiving 6 mg of clonazepam daily in 3 divided doses and in children 6-13 years of age receiving 1.5-4 mg of the drug daily in 3 divided doses. The onset of anticonvulsant action usually occurs within 20-60 minutes, and the duration of action usually is 6-8 hours in infants and young children and up to 12 hours in adults.

Cellular LocationsCytoplasm

用途と製造

Uses · 6 件

Clonazepam (DEA Code Number: 2737) is a Schedule IV controlled substance.

Schedule IV Controlled Substance: (A) The drug or other substance has a low potential for abuse relative to the drugs or other substances in schedule III. (B) The drug or other substance has a currently accepted medical use in treatment in the United States. (C) Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in schedule III.

MEDICATION

MEDICATION (VET)

Anticonvulsants; GABA Modulators

Use (kg; approx.) in Germany (2009): >25

Methods of Manufacturing · 1 件

ortho-Chlorobenzoyl chloride is reacted with para-nitroaniline to form 2-amino-5-nitro-2'-chlorozophenone, and this is condensed with bromacetyl to form 2-bromoacetamido-5-nitro-2'-chlorobenzophenone, then with ammonia to form the corresponding acetamido compound. The acetamido compound is converted to its hydrochloride with anhydrous HCl in methanol, dissolved in boiling methanol, and cyclized to clonazepam with pyridine as the catalyst.

Formulations/PreparationsTable: Clonazepam Preparations [Table#4521]
Use ClassificationPharmaceuticals
General Manufacturing InformationA benzodiazepine /derivative/.
応用分野 · 4 件

用途薬理・生理作用研究用。

説明Clonazepam (Item No. 14263) is an analytical reference material categorized as a benzodiazepine. Clonazepam is regulated as a Schedule IV compound in the United States. This product is intended for research and forensic applications.

使用Antiepileptic agent with anxiolytic and antimanic properties. Anticonvulsant. This is a controlled substance (depressant)

一般的な説明Clonazepam is useful in absence seizures and in myoclonicseizures. Tolerance to the anticonvulsant effect of the clonazepamoften developed rather quickly, and it is a commonproblem with the BZDs. Metabolism involves hydroxylationof the C-3 position, followed by glucuronidation andnitro group reduction, followed by acetylation.

上流・下流製品情報

上流原料

2-ベンゾイルアセトアニリドベンゾフェノン銅(I)クロリドブロモアセチルブロミド2-クロロベンゾイルクロリドアンモニアピリジン水素2-アミノ-2'-ニトロベンゾフェノン亜硝酸ナトリウム硝酸カリウム
補足説明 · 1 件

定義ChEBI: 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus nd associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation.

The therapeutic range of clonazepam is from 0.02 to 0.08 mcg/mL. Any level over 0.08 mcg/mL is considered toxic. The symptoms of overdose develop rapidly.

Allosteric interactions between central benzodiazepine receptors and gamma-aminobutyric acid (GABA) receptors potentiate the effects of GABA. As GABA is an inhibitory neurotransmitter, this results in increased inhibition of the ascending reticular activating system. Benzodiazepines, in this way, block the cortical and limbic arousal that occurs following stimulation of the reticular pathways.